Fish oil-supplemented parenteral nutrition in patients following esophageal cancer surgery: Effect on inflammation and immune function

Nutrition and Cancer

Volumn 65, Issue 1, 2013, Pages 71-75

  Long, Hao ^a,b   Yang, Han ^a   Lin, Yongbin ^a   Situ, Dongrong ^a   Liu, Wanli ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; OMEGA 3 FATTY ACID; PROCALCITONIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DIET SUPPLEMENTATION; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PARENTERAL NUTRITION; PILOT STUDY; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT;

CALCITONIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIETARY SUPPLEMENTS; ESOPHAGEAL NEOPLASMS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PARENTERAL NUTRITION; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PROTEIN PRECURSORS;

EID: 84873702761     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.741761     Document Type: Article

References (41)

1. Tashiro T, Mashima Y, Yamamori H, Horibe K, Nishizawa M, et al.: Alteration of whole-body protein kinetics according to severity of surgical trauma in patients receiving TPN. JPEN 15, 169, 1991.
2. Tashiro T, Yamamori H, Takagi K, Morishima Y, Nakajima N, et al.: Effect of severity of stress on whole-body protein kinetics in surgical patients receiving total parenteral nutrition. Nutrition 12, 763, 1996.
3. Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, et al.: Changes in immune function following surgery for esophageal carcinoma. Nutrition 15, 760-766, 1999.
4. Weiss G, Meyer F, Matthies B, Pross M, Koenig W, et al.: Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr 87, S89-S94, 2002.
5. Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, et al.: Shorttime infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interactionwith endothelium in humans. J Immunol 171, 4837-4843, 2003.
6. Wang X, Li W, Zhang F, Pan L, Li N, and Li J: Fish oil-supplemented parenteral nutrition in severe acute pancreatitis patients and effects on immune function and infectious risk: a randomized controlled trial. Inflammation 32, 304-309, 2009.
7. Heller AR, Rossler S, Litz RJ, Stehr SN, Heller SC, et al.: Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 34, 972-979, 2006.
8. Aiko S, Yoshizumi Y, Tsuwano S, Shimanouchi M, Sugiura Y, et al.: The effects of immediate enteral feeding with a formula containing high levels ofω-3 fatty acids in patients after surgery for esophageal cancer. JPEN 29, 141-147, 2005.
9. Rice TW, Blackstone EH, Rusch VW:AJCC cancer stagingmanual, 7th Ed: esophagus and esophagogastric junction. Ann Surg Oncol., 17, 1721-1724, 2010.
10. Axel R, Heller SE, Litz RJ, Litz N, Stehr SC, et al.: Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 34, 972-979, 2006.
11. Tsekos E, Reuter C, Stehle P, Boeden G, et al.: Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin Nutr 23, 325-330, 2004.
12. Beale R, Bryg DJ, & Bihari DJ: Immunonutrition in the critically ill: a systemic review of clinical outcome. Crit Care Med 27, 2799-2805, 1999.
13. Lee JY, Sohn KH, Rhee SH, and Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem 276, 16683-16689, 2001.
14. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, et al.: Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 37, 789-797, 1999.
15. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, et al.: Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 28, 586-588, 2000.
16. Hensel M, Volk T, Docke WD, Kern F, Tschirna D, et al.: Hyperprocalcitoninemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology 89, 93-104, 1998.
17. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, et al.: Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 8, R234-R241, 2004.
18. Luyt CE, Guerin V, Combes A, Trouillet JL, Ayed SB, et al.: Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171, 48-53, 2005.
19. Meisner M, Adina H, & Schmidt J: Correlation of procalcitonin and C-reactive protein to inflammation, complications and outcome during the intensive care unit of multiple-trauma patients. Crit Care 10, R1, 2006.
20. Ugarte H, Silva E, Mercan D, De Mendonca A, and Vincent JL: Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27, 498-504, 1999.
21. Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez JL, et al.: Measurement of procalcitonin levels in children with bacterial and viral meningitis. Clin Infect Dis 24, 1240-1242, 1997.
22. Brunkhorst FM, Eberhard OK, & Brunkhorst R: Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by paocalcitonin. Crit Care Med 27, 2172-2176, 1999.
23. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, et al.: Usefulness of paocalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmatic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40, 1250-1256, 1997.
24. Hammer S, Meisner F, Dirschedl P, Hobel G, Fraunberger P, et al.: Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 6, 235-241, 1998.
25. Kuse ER, Langefeld I, Jaeger K, and Kulpmann WR: Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 28, 555-559, 2000.
26. Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, et al.:Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 28, 950-957, 2000.
27. Meisner M, Tschaikowsky K, Hutzler A, Schick C, and Schuttler J: Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 24, 680-684, 1998.
28. Carsin H, Assicot M, Feger F, Roy O, Pennacino I, et al.: Evolution and significance of circulating procalcitonin levels compared with IL-6, TNFalpha and endotoxin levels early after thermal injury. Burns 23, 218-224, 1997.
29. Brunkhorst FM, Clark Al, Forycki ZF, and Anker SD: Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 72, 3-10, 1999.
30. Meisner M, Hutzler A, Tschaikowsky K, Schick C, Schuttler J: Postoperative plasma concentration of procalcitonin and C-reactive protein in patients undergoing cardiac and thoracic surgery with and without cardiopulmonary bypass. Cardiovasc Eng 3, 174-178, 1998.
31. Meisner M, Rauschmayer C, Schmidt J, Feyrer R, Cesnjevar R, et al.: Early increase of procalcitonin after cardiovascular surgery in patients with noninfectious and infectious postoperative complications. Intensive Care Med 28, 1094-1102, 2002.
32. Rodriguez JM, Arias-Diaz J, Figueredo MA, Torres-Melero J, Garcia- Carreras C, et al.: Lymphocyte subpopulations and surgery. The role of postoperative parenteral nutrition. Nutr Hosp 9, 324-330, 1994.
33. Tsutsui S, Morita M, Kuwano H, Matsuda H, Mori M, et al.: Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma. J Surg Oncol 49, 176-181, 1992.
34. Bentdal OH, Froland SS, Bosnes V, Bergan A, Soreide O, et al.: Alterations in lymphocyte subsets in blood may predict respectability in carcinoma of cardia of oesophagus. Cancer Lett 100, 133-138, 1996.
35. Heidecke CD, Weighardt H, Feith M, Fink U, Zimmermann F, et al.:Neoadjuvant treatment of esophagus cancer: immunosuppression following combined radiochemotherapy. Surgery 132, 495-501, 2002.
36. Tsutsui S, Sonoda K, Sumiyoshi K, Kitamura K, Toh Y, et al.: Prognostic significance of immunological parameters in patients with esophagus cancer. Hepatogastroenterology 43, 501-509, 1996.
37. Mafune K, Tanaka T: Influence of multimodality therapy on the cellular immunity of patients with esophagus cancer. Ann Surg Oncol 7, 609-616, 2000.
38. + T cells. Eur J Immunol 26, 957-960, 1996.
39. Wang HH, Lin C, Huang TP: Patterns of CD4/CD8 T-cell in dialysis effluents predict the long-term outcome of peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 18, 1181-1189, 2003.
40. Rey-Ferro M, Castano R, Orozco O, Serna A, and Moreno A: Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 13, 878-881, 1997.
41. Wang JY, Dai SQ, Ye WF, Long H, Lin P, et al.: Perioperative changes of cellular immune response of patients with esophageal carcinoma evaluated through detecting AgNOR content in peripheral blood T lymphocytes and T cell subsets. Chinese Journal of Cancer 24, 861-864, 2005.